T1	p 90 153	chemo-na?ve patients with advanced non-small cell lung cancer .
T2	p 296 345	chemo-na?ve non-small cell lung cancer patients .
T3	p 354 425	Patients with chemo-na?ve stage IIIB/IV non-small cell lung cancer were
T4	p 679 728	total of 80 patients were entered in this trial .
T5	p 1320 1346	non-small cell lung cancer
T6	i 62 82	gemcitabine and oral
T7	i 90 101	chemo-na?ve
T8	i 263 283	gemcitabine combined
T9	i 483 503	oral S-1 ( 60 mg/m/d
T10	i 514 531	day ) from days 1
T11	i 535 570	14 with gemcitabine ( 1000 mg/m/d )
T12	i 585 586	8
T13	i 595 596	)
T14	i 1228 1239	combination
T15	i 1243 1258	gemcitabine and
T16	o 208 216	efficacy
T17	o 221 227	safety
T18	o 769 803	response rate . The response rates
T19	o 875 907	Median time to treatment failure
T20	o 958 984	Median time to progression
T21	o 1035 1055	Median survival time
T22	o 1128 1144	toxicity profile
T23	o 1284 1292	feasible
T24	o 1297 1306	effective
T25	o 1409 1440	response rate and survival data